Treatment regimens using anti-NKG2A antibodies

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10676523
APP PUB NO 20170298131A1
SERIAL NO

15511792

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INNATE PHARMAMARSEILLE FRANCE MARSEILLE BOUCHES-DU-RHONE

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Andre, Pascale Marseilles, FR 31 339
Blery, Mathieu Marseilles, FR 25 157
Paturel, Carine Marcy l'Etoile, FR 52 237
Soulas, Caroline Marseilles, FR 6 64
Wagtmann, Nicolaï Cassis, FR 4 30

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 9, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 9, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00